Titanium Dioxide
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
- Titanium Dioxide
- Titanium Dioxide: From Topical Sun Protection and Homeopathic Use to Drug-Induced Osteoporosis
Titanium Dioxide: From Topical Sun Protection and Homeopathic Use to Drug-Induced Osteoporosis
One-Sentence Summary
Titanium dioxide is an inert mineral compound used mainly as a sunscreen ingredient and in a homeopathic preparation; no approved medical indication is recorded in the data compiled for this report. The TxGNN model predicts it may be effective for drug-induced osteoporosis, with a very high graph-based score. However, there are 0 clinical trials and 0 relevant publications supporting this prediction, so it is a model-only prediction.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | No approved indication text recorded (products are a sunscreen lotion and a homeopathic pellet) |
| Predicted New Indication | Drug-induced osteoporosis |
| TxGNN Prediction Score | 99.9998% |
| Evidence Level | L5 |
| US Market Status | Cancelled only (no currently valid licenses) |
| Number of NDAs | 2 (both cancelled) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Titanium dioxide is a poorly absorbed, chemically inert pigment and implant material. Its known uses are physical UV blocking in sunscreens and as a component of medical devices, not as a systemically active drug.
The review of this prediction found no plausible pharmacological pathway linking titanium dioxide to the treatment of osteoporosis. The very high TxGNN score (about 0.999998) appears to reflect proximity within the knowledge graph rather than a biological mechanism. Without trials, literature, or a mechanistic link, the prediction cannot be considered supported.
Other top-ranked predictions show the same pattern: diabetic retinopathy, severe nonproliferative diabetic retinopathy, diabetic cataract, and several cataract subtypes (craniostenosis, mature, tetanic, immature, type 2 diabetes-associated, and cortical). All are at evidence level L5 with a Hold recommendation.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for drug-induced osteoporosis.
For context, the second-ranked prediction (diabetic retinopathy) returned five publications. None shows a therapeutic effect of titanium dioxide:
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 36197877 | 2022 | Methods/Analytical | Analytical Chemistry | TiO2 microparticles used to purify plasma extracellular vesicles for diabetic retinopathy metabolic profiling (a laboratory tool, not a treatment) |
| 41637842 | 2026 | Review | J Trace Elem Med Biol | Review of metallic nanoparticles in diabetes mellitus; mechanistic and therapeutic perspectives, not specific to titanium dioxide treatment of retinopathy |
| 38078945 | 2023 | Methods/Analytical | Analytical Chemistry | Selective magnetic system for analysing circulating RNAs on extracellular vesicles and lipoproteins |
| 39566751 | 2025 | Preclinical/Imaging | Methods | Ultrasmall TiO2 nanoparticle-fluorescein conjugates evaluated for improved fundus fluorescein angiography (imaging, not therapy) |
| 20059246 | 2009 | Phantom/Device study | J Biomed Opt | Dynamic eye phantom for retinal oximetry calibration |
US Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| M020 (cancelled) | Kiehl’s Since 1851 Dermatologist Solutions SuperFluid UV Mineral Defense Broad Spectrum SPF 50 Plus Sunscreen | Lotion | Not recorded |
| Not available (cancelled) | Titanium metallicum (Boiron) | Pellet | Not recorded |
Safety Considerations
Please refer to the package insert for safety information.
No drug interaction records were found for this compound.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a graph-based model score. There are no clinical trials, no supportive literature, and no plausible mechanism for titanium dioxide in drug-induced osteoporosis. The compound is inert and poorly absorbed, and its available literature concerns diagnostic and analytical tools rather than therapy. It also has no currently valid US licenses.
To proceed, the following is needed:
- Mechanism of action data and a credible biological pathway linking titanium dioxide to bone metabolism
- Preclinical evidence (in vitro or animal models) of an effect on drug-induced bone loss
- Safety and warning information from FDA labeling, which has not been obtained
- Evaluation of route compatibility, since current products are topical or homeopathic rather than systemic
- Reassessment of whether graph-proximity artefacts explain the high scores across the osteoporosis, retinopathy, and cataract predictions
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.